Cervical Cancer Diagnostic Market Size, Industry Analysis Report, Regional Outlook, Application Development Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027

Cervical Cancer Diagnostic Market size is projected to experience substantial growth from 2019 to 2025.
 

The industry will witness significant growth due to rising awareness about cervical cancer and disease diagnosis with the help of cancer screening tests will drive the cervical cancer diagnostic market during the forecast timeframe. According to the American Cancer Society statistics, nearly 4,250 women in the U.S. will die due to cervical cancer in 2019 and around 13,170 new cases of cervical cancer will be diagnosed.
 

Increasing prevalence of Human papilloma virus (HPV) infection, the foremost cause of cervical cancer will drive cervical cancer diagnostic market. As per the CDC data, about 11,000 women suffer from HPV infection annually in the U.S. The mortality due to cervical cancer has dropped by about 50% due to availability of various predisposition diagnosis tests. Governments has been taking numerous initiatives including Be Clean on Cancer campaign, launched by UK government to create awareness about cancer and disease diagnostics.
 

Technological advancements in diagnostic tools and screening procedures will fuel industry growth over the coming years. Growing demand for minimal invasive screening procedures along with biomarkers to enhance disease diagnosis outcomes will drive the cervical cancer diagnostic market over the forecast period. Favorable reimbursement policies will stimulate demand for cervical screening tests, thereby positively impacting market size growth.
 

Based on the test type, the cervical cancer diagnostic market can be segmented into pap testing, cervical biopsies, cystoscopy and HPV testing. Pap testing market held largest revenue share in 2018 owing to rising awareness about cancer and cancer screening tests stimulating rise in number of women performing pap tests. Increasing occurrence of cervical cancer in women aged between 21 to 65 years coupled with early detection of cervical cancer allowing preventive treatment for the disease will fuel cervical cancer diagnostic market. HPC testing market will witness significant growth during the forecast period owing to growing demand for cost effective and technologically advanced diagnostic procedures delivering precise results. Development of biomarkers enabling detection of cervical cancer lesions will positively affect industry growth.
 

U.S. cervical cancer diagnostic market held largest regional share in 2018 due increasing number of women in U.S. suffering from cervical cancer. According to the American Cancer Society, cervical cancer is most common among the U.S. women. Hispanic women in the country are more prone to suffer from cervical cancer followed by other, Asians and Pacific Islanders, African Americans and whites. Increasing use of pap test for early detection of cervical cancer has reduced occurrence of disease by almost 50% in the U.S. Several initiatives such as National Breast and Cervical Cancer Early Detection Program (NBCCEDP) initiated by Centers for Disease Control and Prevention coupled with favorable reimbursement scenario will drive U.S. cervical cancer diagnostic market.
 

Increasing incidences of cervical cancer and high technology adoption will drive Germany cervical cancer diagnostic market over the coming years. According to HPV Information Center Germany 2017 data, nearly 35.9 million women in Germany are at risk of suffering from cervical cancer. Favorable programs such as HPV vaccination program, German cancer screening program and other awareness campaigns undertaken to create disease awareness and early detection techniques will fuel market size growth. German women covered under statutory health insurance receive annual cervical examination that includes PAP tests.
 

Rising incidences of HPV infection and increasing number of screening procedures for cervical cancer will drive South Africa cervical cancer diagnostic market. National cervical screening program was launched by South African Department of health in order to reduce disease burden and create awareness about the disease.
 

Few notable industry players include, F. Hoffmann-La Roche Ltd, Quest Diagnostics, Arbor Vita Corporation, Dell Guided Therapeutics, Becton, Dickinson and Company (BD), Abbott Molecular, QIAGEN, Hologic, OncoHealth Corporation, and CooperSurgical. The market players are focusing on R&D to develop innovative and technologically advanced cervical cancer diagnostics delivering high accuracy. In April 2017, Roche’s CINtec Histology test, a p16 biomarker test developed to be used with hematoxylin & eosin (H&E) staining to determine treatment necessity in women with pre-cervical cancer occurrence received the U.S. FDA approval.
 

Cervical Cancer Diagnostic Market by Test-type, 2014-2025 (USD Million)

• Pap testing
• Cervical biopsy
• Cystoscopy
• HPV testing

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Russia
  • Poland
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Qatar
  • Kuwait
  • UAE

Company Profiles

• F. Hoffmann-La Roche Ltd.
• Quest Diagnostics
• Arbor Vita Corporation
• Dell Guided Therapeutics
• Becton, Dickinson and Company (BD)
• Abbott Molecular
• Qiagen
• Hologic
• OncoHealth Corporation
• CooperSurgical
• Oncgnostics GmbH
• DaAn Gene Co., Ltd
• Seegene Inc.
• Femasys Inc.
• Zilico Ltd.

What Information does this report contain?